EcoDrugPlus

Granzyme B-Like

Ensembl ID : ENSPNYG00000020500
Gene Symbol: LOC102212346
2 Cross references
950 Possible Orthologues:

Granzyme E-Like

Ensembl ID : ENSPNYG00000020612
Gene Symbol: LOC102212914
2 Cross references
949 Possible Orthologues:

Granzyme G-Like

Ensembl ID : ENSPNYG00000020462
Gene Symbol: LOC102211310
2 Cross references
921 Possible Orthologues:

Granzyme G-Like

Ensembl ID : ENSPNYG00000019024
Gene Symbol: LOC102194532
2 Cross references
923 Possible Orthologues:

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSPNYG00000008758
Gene Symbol: LOC102215607
3 Cross references
232 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSPNYG00000006289
Gene Symbol: GHSR
3 Cross references
212 Possible Orthologues:

Growth Hormone-Releasing Hormone Receptor-Like

Ensembl ID : ENSPNYG00000022710
Gene Symbol: LOC102197481
2 Cross references
191 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSPNYG00000008686
Gene Symbol: GUCY1A1
1 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSPNYG00000014953
Gene Symbol: GUCY1A2
4 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSPNYG00000008643
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSPNYG00000023295
Gene Symbol: HSP90AB1
3 Cross references
339 Possible Orthologues:

High Affinity Nerve Growth Factor Receptor-Like

Ensembl ID : ENSPNYG00000013517
Gene Symbol: LOC102197043
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).